Type 1 Diabetes Research

A Step Into Freedom From T1DM

About Me

Hello

I amShivani Desai

Type 1 diabetes researcher and enthusiast

Welcome to T1DM.org! It is a platform which consolidates my work about type 1 diabetes (T1DM) and its management. This forum invites an open interaction from national and international experts to manage type 1 diabetes, share their knowledge and collaborate to work towards freedom from this painful disease.

This forum includes the papers published by the author in the journals of repute. These papers primarily involve the content related to the etiology and pathophysiology of T1DM, the application of mesenchymal stem cells to manage T1DM and improve the quality of life in patients, and the correlation of diabetes with hepatic dysfunctions. It also includes papers related to the immunological aspects in the journey to prevent and reverse the disease.

With more interaction and collaborations, we can bring an end to T1DM and give a better life to the children who are at risk to develop this immensely agonising disease.

My Profile Contact Me

2 Patents

Diabetec foot ulcer (DFU) treatment using stem cell, Wound healing

26 Publications

T1DM vaccine research, Regenerative medicine research, 15 under process

10 Awards

'Woman Innovator' National Award 2022 and others, for research in T1DM

Journey So Far

2016

July

Inception of Idea

Development of vaccine to prevent and reverse type 1 diabetes mellitus

2018

September

t1dm.org Launched

Platform launched to consolidate research work about type 1 diabetes and its management

t1dm.org invites an open interaction from national and international experts to manage type 1 diabetes, share their knowledge and collaborate to work towards freedom from this painful disease

2020

June

Research Publication

First review paper on type 1 diabetes mellitus “Mapping of type 1 diabetes mellitus” published in Current Diabetes Reviews

2021

December

Preclinical Model Development

Preclinical model development project using Swiss albino mice started to study type 1 diabetes

2022

April

Phase 1 Preclinical Study

Stability test for vaccine formula conducted
Allergy test and safety study for vaccine formula conducted
Efficacy study of vaccine formula to prevent and reverse type 1 diabetes mellitus

My Latest Publications

Showing posts with label Pharmaceutical Nanotechnology. Show all posts
Showing posts with label Pharmaceutical Nanotechnology. Show all posts

[Review Paper] Nanotechnology: Newer Approach in Insulin Therapy

Abstract: Insulin is a peptide hormone released by pancreatic beta cells. An autoimmune reaction in diabetes mellitus type 1 causes the beta cells to die, preventing insulin from being produced or released into the bloodstream which impacts 30 million people globally and is linked to shortened lifespan due to acute and chronic repercussions. Insulin therapy aims to replicate normal pancreatic insulin secretion, which includes low levels of insulin that are always present to support basic metabolism, as well as the two-phase secretion of additional insulin in response to high blood sugar - an initial spike in secreted insulin, followed by an extended period of continued insulin secretion. This is performed by combining various insulin formulations that work at varying rates and for different lengths of time. Since the beginning of human insulin use, several advances in insulin formulations have been made to help meet these aims as much as possible, resulting in improved glycaemic control while limiting hypoglycaemia. In this review, we looked at devices used by patients with type 1 diabetes, such as insulin pumps, continuous glucose monitors, and, more recently, systems that combine a pump with a monitor for algorithm-driven insulin administration automation. We intend to provide insight into supplementary therapies and nanotechnology employed in insulin therapy as a result of our review. 


Journal: Pharmaceutical Nanotechnology 

Keywords: Basal Bolus Insulin; Continuous Glucose Monitoring (CGM); Insulin Pump Therapy; Insulin glargine U300; Nanotechnology 

[Review Paper] Nanobiotechnology-Modified Cellular and Molecular Therapy as a Novel Approach for Autoimmune Diabetes Management

Abstract: Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes. However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in diabetes pathogenesis such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen [HLA] gene, miRNA gene and hepatocyte growth factor [HGF] gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies and gene therapy for type 1 diabetes management.


Journal: Pharmaceutical Nanotechnology

Keywords: Autoimmunity; Immunotherapy; Nanocarriers; Stem cell; Tolerance; Type 1 diabetes

Read Full Review Paper

Testimonials

Collaborate With Me

Contact Us

SHIVANI DESAI
+91-20-4930-0148
Pune, India